Results 31 to 40 of about 291,220 (220)

Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim

, 2022
Immune-mediated platelet transfusion refractoriness due to anti-human leukocyte antigen (HLA) antibodies can occur in approximately 9% of patients with myelodysplastic syndromes (MDS) and can lead to an increased risk of clinically relevant bleeds ...
Čengić, Marina, Skorić, Ivana, Ivana Skorić, Ivan Krečak, Marina Čengić, Filip Krečak, Skelin, Marko, Marko Skelin, Krečak, Ivan, Krečak, Filip   +9 more
core   +1 more source

Platelet transfusion refractoriness in patients with acute myeloid leukemia: The role of anti-platelet antibodies [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. Platelet transfusion refractoriness represents a common issue in the treatment course of acute myeloid leukemia (AML) patients who require chronic transfusion support.
Đunić Irena, Srdić-Rajić Tatjana, Pantić Nikola, Todorović-Balint Milena   +3 more
doaj   +1 more source

iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity

Stem Cell Reports, 2020
Summary: The ex vivo production of platelets depleted of human leukocyte antigen class I (HLA-I) could serve as a universal measure to overcome platelet transfusion refractoriness caused by HLA-I incompatibility.
Daisuke Suzuki, Charlotte Flahou, Norihide Yoshikawa, Ieva Stirblyte, Yoshikazu Hayashi, Akira Sawaguchi, Marina Akasaka, Sou Nakamura, Natsumi Higashi, Huaigeng Xu, Takuya Matsumoto, Kosuke Fujio, Markus G. Manz, Akitsu Hotta, Hitoshi Takizawa, Koji Eto, Naoshi Sugimoto   +16 more
doaj   +1 more source

Platelet refractoriness

Global Journal of Transfusion Medicine, 2019
Platelet transfusion support is extensively required for hemato-oncology patients who are multiply transfused. Platelet refractoriness can represent a significant clinical condition that complicates the platelet transfusion support in such patients.
B Sunil Rajadhyaksha, D Priti Desai, A Anisha Navkudkar   +2 more
doaj   +1 more source

Perioperative administration of recombinant activated factor VII in a Glanzmannʼs thrombasthenia patient with platelet refractoriness: case report

Brazilian Journal of Anesthesiology, 2022
Glanzmannʼs Trombasthenia (GT) is a genetic disorder, that develops with a tendency toward bleeding and is characterized by the absence or decrease in platelet aggregation. Surgical bleeding may be difficult to control.
Flora Margarida Barra Bisinotto, Laura Bisinotto Martins, Giovanini Pires de Camargos, Marcelo de Paula Bianco   +3 more
doaj   +1 more source

Pooled platelet concentrates provide a small benefit over single-donor platelets for patients with platelet refractoriness of any etiology

Journal of International Medical Research, 2021
Background At our institution, patients with platelet refractoriness (of any etiology) are sometimes switched from apheresis platelets to pooled platelets before human leukocyte antigen (HLA)-matched units become available. Study design and methods Seven
Ying-Hsia Chu, William Nicholas Rose, William Nawrot, Thomas J. Raife   +3 more
doaj   +1 more source

Transfusion effect of 0.5-dose of apheresis platelet in pediatric patients

Zhongguo shuxue zazhi, 2023
Objective To investigate the transfusion effect of 0.5-dose of apheresis platelet in pediatric patients. Methods A total of 195 children who underwent 0.5-dose platelet transfusion from August 2021 to June 2022 were enrolled, and the platelet count ...
Lijuan QIU, Zida ZHEN, Xiaoyan FU, Shuxuan MA   +3 more
doaj   +1 more source

Evaluation of the effectiveness of platelet crossmatching by the solid‐phase red cell adherence assay in adult patients of a tertiary care hospital in Thailand: A retrospective study

Health Science Reports, 2022
Background and Aims Platelet transfusion refractoriness is well aware to be associated with poor clinical outcomes. Patients with the alloantibody causing refractoriness required cross‐matched compatible products to improve the platelet number.
Thunnakhon Sinwatcharaphirom, Kusuma Apisawes, Janejira Kittivorapart   +2 more
doaj   +1 more source

Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility

Asian Journal of Transfusion Science, 2015
Platelet transfusions have contributed to the revolutionary modern treatment of hypoproliferative thrombocytopenia. Despite the long-term application of platelet transfusion in therapeutics, all aspects of their optimal use (i.e., in cases of ABO and/or ...
Serena Valsami, Dimitrios Dimitroulis, Argyri Gialeraki, Maria Chimonidou, Marianna Politou   +4 more
doaj   +1 more source

Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China

, 2010
Platelet transfusion refractoriness (PTR) is the major complication of long-term platelet supportive care. To improve the effectiveness of platelet transfusion therapy in PTR patients, we aimed to establish a platelet donor registry in our region ...
Xu, Xiuzhang, Ye, Xin, Fu, Yongshui, Xia, Wenjie, Santoso, Sentot, Chen, Yangkai, Deng, Jing, Luo, Guangping, Tian, Linwei, Bei, C. H., W. J. Xia, S. Santoso, L. W. Tian, G. P. Luo, Y. K. Chen, Y.S. Fu, X. Z. Xu, J. Deng, C. H. Bei, X. Ye   +19 more
core   +1 more source